BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38477966)

  • 1. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
    Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
    N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
    Brown CE; Alizadeh D; Starr R; Weng L; Wagner JR; Naranjo A; Ostberg JR; Blanchard MS; Kilpatrick J; Simpson J; Kurien A; Priceman SJ; Wang X; Harshbarger TL; D'Apuzzo M; Ressler JA; Jensen MC; Barish ME; Chen M; Portnow J; Forman SJ; Badie B
    N Engl J Med; 2016 Dec; 375(26):2561-9. PubMed ID: 28029927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
    Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
    J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
    Zhang Y; Zhang Z; Ding Y; Fang Y; Wang P; Chu W; Jin Z; Yang X; Wang J; Lou J; Qian Q
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3725-3734. PubMed ID: 34032893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
    Vitanza NA; Johnson AJ; Wilson AL; Brown C; Yokoyama JK; Künkele A; Chang CA; Rawlings-Rhea S; Huang W; Seidel K; Albert CM; Pinto N; Gust J; Finn LS; Ojemann JG; Wright J; Orentas RJ; Baldwin M; Gardner RA; Jensen MC; Park JR
    Nat Med; 2021 Sep; 27(9):1544-1552. PubMed ID: 34253928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
    Bagley SJ; Logun M; Fraietta JA; Wang X; Desai AS; Bagley LJ; Nabavizadeh A; Jarocha D; Martins R; Maloney E; Lledo L; Stein C; Marshall A; Leskowitz R; Jadlowsky JK; Christensen S; Oner BS; Plesa G; Brennan A; Gonzalez V; Chen F; Sun Y; Gladney W; Barrett D; Nasrallah MP; Hwang WT; Ming GL; Song H; Siegel DL; June CH; Hexner EO; Binder ZA; O'Rourke DM
    Nat Med; 2024 May; 30(5):1320-1329. PubMed ID: 38480922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of regulable EGFRvIII targeted chimeric antigen receptor T cells for adoptive cell therapy of glioblastoma.
    Zheng Y; Gao N; Fu YL; Zhang BY; Li XL; Gupta P; Wong AJ; Li TF; Han SY
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):59-66. PubMed ID: 30409424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
    Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
    Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
    Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
    Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma.
    Wang S; O'Rourke DM; Chawla S; Verma G; Nasrallah MP; Morrissette JJD; Plesa G; June CH; Brem S; Maloney E; Desai A; Wolf RL; Poptani H; Mohan S
    Br J Cancer; 2019 Jan; 120(1):54-56. PubMed ID: 30478409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
    Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
    J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
    Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
    Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
    J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
    Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
    Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.